Drug or treatment

Rituximab clinical trials

• 176Clinical trials
• 2New in 30 days
• 50Countries

Newest trials

All recruiting trials (newest 150 of 176)

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Chidamide, Lenalidomide, and Rituximab as induction therapy for newly diagnosed elderly or unfit double-expressor DLBCL

  This trial tests whether the combo of chidamide, lenalidomide, and rituximab can help treat newly diagnosed double-expressor DLBCL in people who are elderly or not fit for standard chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07884708

• Rituximab plus Cyclosporine for Primary Membranous Nephropathy

  This study tests whether adding Cyclosporine to Rituximab helps people with primary membranous nephropathy achieve remission of heavy protein in the urine faster.

  Recruiting Phase 2/3 Peking University First Hospital · Beijing · NCT07861204

• Glofitamab combo vs Rituximab combo with chemo for relapsed/refractory DLBCL

  This study tests whether glofitamab with chemotherapy (JS203-GemOx) helps patients with relapsed or refractory DLBCL more than rituximab with chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07808827

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

• Tafasitamab and Rituximab for newly diagnosed follicular lymphoma

  This study tests a combination of tafasitamab and rituximab to treat adults with newly diagnosed follicular lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07731789

• Rituximab for treating immune-related side effects from checkpoint inhibitors

  This small early-phase trial tests whether a single 100 mg dose of rituximab can help manage immune-related adverse events in adults with malignant melanoma who are on checkpoint inhibitors, alongside a tapering corticosteroid plan.

  Recruiting Phase 1 Herlev Hospital · Herlev, Herlev · NCT07694414

• Prevention of EBV Reactivation in Kids Undergoing Haploidentical Stem Cell Transplant with Rituximab Added to ATG Conditioning

  This study tests whether giving two doses of rituximab during preconditioning can prevent EBV reactivation in children after a haploidentical stem cell transplant using ATG, and checks the safety of adding rituximab.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou · NCT07693881

• MK-1045 and Rituximab in Follicular Lymphoma

  This study tests whether adding MK-1045 to rituximab can help people with follicular lymphoma after standard therapy.

  Recruiting at 38 sites Phase 2/3 Merck Sharp & Dohme LLC · Duarte, California and 37 other locations · NCT07634471

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

• R-PMDT Regimen for Newly Diagnosed PCNSL

  This study tests the R-PMDT treatment approach in people newly diagnosed with primary CNS lymphoma to see how many respond.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07604987

• Nemtabrutinib plus rituximab for marginal zone lymphoma

  This phase 2 trial tests whether combining nemtabrutinib with rituximab can help people with marginal zone lymphoma.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07583810

• Golgadomide plus rituximab for relapsed or refractory mantle cell lymphoma

  This phase I/II trial tests whether golcadomide given with rituximab is safe and can help people with mantle cell lymphoma that has come back or stopped responding to treatment.

  Recruiting Phase 1/2 City of Hope Medical Center · Duarte, California · NCT07578077

• First-line therapy with Loncastuximab Tesirine and Rituximab for PTLD after transplant

  This trial tests if loncastuximab tesirine plus rituximab can help adults with post-transplant lymphoproliferative disorder after a transplant.

  Recruiting Phase 1/2 University of Utah · Salt Lake City, Utah · NCT07573436

• SCTB35 with Gemcitabine and Oxaliplatin in relapsed or refractory DLBCL

  This trial tests whether SCTB35 added to gemcitabine and oxaliplatin helps people with relapsed or refractory diffuse large B-cell lymphoma stay disease-free longer compared with rituximab plus gemcitabine and oxaliplatin.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing · NCT07570823

• HiHat: Rituximab Followed by Cladribine in Relapsing-Remitting MS

  This trial tests whether giving rituximab and then cladribine in sequence is safe and doable for people with relapsing-remitting MS.

  Recruiting at 3 sites Phase 2 Uppsala University · Falun and 3 other locations · NCT07517185

• Orelabrutinib plus rituximab with optional lenalidomide for untreated marginal zone lymphoma using a response-adapted plan

  This will test whether giving orelabrutinib with rituximab, and adding lenalidomide for those who don't fully respond, helps people with newly diagnosed marginal zone lymphoma achieve complete remissions.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07448324

• Zanubrutinib, rituximab, lenalidomide plus tislelizumab for relapsed/refractory follicular lymphoma

  This trial tests whether adding the PD‑1 blocker tislelizumab to zanubrutinib, rituximab, and lenalidomide helps adults with relapsed or refractory follicular lymphoma who have had at least two prior therapies.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07418190

• PD‑1 blocker with rituximab, high‑dose methotrexate, and orelabrutinib for newly diagnosed primary or secondary CNS lymphoma

  This trial will test whether combining a PD‑1 blocker with rituximab, high‑dose methotrexate, and orelabrutinib helps people with newly diagnosed primary or secondary central nervous system diffuse large B‑cell lymphoma.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07410520

• CRP regimen for older adults with untreated double‑expressor diffuse large B‑cell lymphoma

  This trial will try the CRP drug combination (chidamide, rituximab, and polatuzumab vedotin) as first-line treatment for older adults with previously untreated double-expressor DLBCL.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07397832

• Epcoritamab plus R-GemOx before autologous stem cell transplant for relapsed or refractory DLBCL

  This phase II trial tests whether adding epcoritamab to rituximab with gemcitabine and oxaliplatin (R-GemOx) can help adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) achieve remission and proceed to autologous stem cell transplant.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07365306

• Daratumumab versus rituximab for children with primary immune thrombocytopenia

  This study will test whether daratumumab works better than rituximab to increase platelet counts in children aged 6–17 with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07362238

• Daratumumab plus rituximab for adults with relapsed or refractory immune thrombocytopenia

  This treatment combines daratumumab (an anti‑CD38 antibody) with rituximab to see if it raises platelet counts in adults with ITP who haven't responded to steroids and other therapies.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07362199

• Testing a four-drug regimen (methotrexate, rituximab, sintilimab, pirtobrutinib) versus investigator-selected care for newly diagnosed PCNSL

  This trial will try a combination of methotrexate, rituximab, sintilimab and pirtobrutinib as first treatment for adults with newly diagnosed primary central nervous system lymphoma to see if it increases complete remissions and is safe compared with standard doctor-selected treatments.

  Recruiting at 3 sites Phase 2 Tongji Hospital · Xiamen, Fujian and 3 other locations · NCT07350850

• Daratumumab versus rituximab for adult primary immune thrombocytopenia

  This trial will test whether daratumumab (an anti‑CD38 antibody) works better than rituximab for adults with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07297563

• Pirtobrutinib plus rituximab for adults with newly diagnosed indolent mantle cell lymphoma

  This trial will test whether combining pirtobrutinib with rituximab is effective and safe for adults newly diagnosed with indolent mantle cell lymphoma.

  Recruiting at 12 sites Phase 2 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Lisbon, Lisbon District and 15 other locations · NCT07285590

• Orelabrutinib with lisaftoclax and rituximab for untreated high-risk mantle cell lymphoma

  This trial will try combining orelabrutinib, lisaftoclax, and rituximab in people with untreated, high-risk mantle cell lymphoma to see if it increases complete remissions and delays progression.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07272499

• Zanubrutinib plus rituximab for secondary HLH linked to B‑cell lymphoma

  This test tries zanubrutinib together with rituximab (plus short steroids and ruxolitinib, with emapalumab if needed) to treat people who have secondary HLH caused by B‑cell lymphoma.

  Recruiting Phase 4 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07270835

• Obinutuzumab for non-infectious cryoglobulinemic vasculitis that didn’t respond to rituximab

  This study tests whether obinutuzumab can help adults with active cryoglobulinemic vasculitis who are refractory or intolerant to rituximab.

  Recruiting at 23 sites Phase 2 Assistance Publique - Hôpitaux de Paris · Blois and 24 other locations · NCT07268521

• BTKi‑rituximab induction followed by glofitamab consolidation for high‑risk newly diagnosed mantle cell lymphoma

  This will test whether giving glofitamab after initial BTKi plus rituximab helps control high‑risk, newly diagnosed mantle cell lymphoma.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07257055

• Pirtobrutinib plus lisaftoclax and rituximab for relapsed or refractory DLBCL

  This trial tests whether combining pirtobrutinib, lisaftoclax, and rituximab helps people with relapsed or refractory diffuse large B‑cell lymphoma who have had at least one prior systemic therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07255963

• Rituximab plus anti‑CD38 antibody versus rituximab alone for primary immune thrombocytopenia

  This trial will test whether adding an anti‑CD38 antibody (daratumumab) to rituximab helps adults with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07234019

• Zanubrutinib plus rituximab as first-line treatment for marginal zone lymphoma

  This tests whether combining zanubrutinib and rituximab is effective and safe as first-line treatment for people with CD20-positive marginal zone lymphoma who have not received prior systemic therapy.

  Recruiting Henan Cancer Hospital · Zhengzhou, Henan · NCT07233720

• Pirtobrutinib combined with venetoclax and rituximab for Waldenström's macroglobulinemia

  This treatment tries combining pirtobrutinib, venetoclax, and rituximab in people newly diagnosed with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma to see if it controls the disease.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 8 other locations · NCT07231952

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Dose‑adjusted EPOCH chemotherapy with or without rituximab plus ponatinib for newly diagnosed Philadelphia chromosome–positive B‑cell ALL/lymphoblastic lymphoma

  This treatment plan tests whether adding the BCR‑ABL inhibitor ponatinib to dose‑adjusted EPOCH chemotherapy, with rituximab for CD20‑positive disease, helps adults newly diagnosed with Philadelphia chromosome–positive B‑cell acute lymphoblastic leukemia or lymphoblastic lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07224100

• SB-4826 for adults with advanced solid tumors or non-Hodgkin lymphoma

  This trial tests whether the oral drug SB-4826, given alone or with rituximab, is safe and can help adults with advanced solid tumors or non-Hodgkin lymphoma.

  Recruiting Phase 1/2 University of California, San Diego · La Jolla, California · NCT07222631

• Orelabrutinib plus zebetuzumab and lenalidomide vs bendamustine‑rituximab for newly diagnosed marginal zone lymphoma

  This study will test whether a combination of orelabrutinib, zebetuzumab, and lenalidomide helps people with newly diagnosed marginal zone lymphoma compared with a standard bendamustine plus rituximab regimen.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07208981

• Romiplostim N01 plus rituximab for people with primary immune thrombocytopenia unresponsive to oral TPO‑RAs

  This study will test whether weekly romiplostim N01 injections combined with a four‑week course of rituximab can raise platelet counts in people aged 14 and older whose ITP did not respond to oral TPO‑RAs.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07206823

• Orelabrutinib with rituximab and optional autologous stem cell transplant for mantle cell lymphoma

  This phase 2 trial tests whether adding the oral BTK inhibitor orelabrutinib to rituximab, with optional autologous stem cell transplant and orelabrutinib maintenance, works and is safe for people with newly diagnosed non-high-risk mantle cell lymphoma.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07199296

• Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

  In this study, adults with newly diagnosed primary CNS lymphoma try different induction regimens to see which one works best before consolidation therapy.

  Recruiting at 9 sites Phase 2/3 Huashan Hospital · Beijing and 14 other locations · NCT07185373

• Intensive chemotherapy with earlier and increased rituximab for aggressive mature B‑cell non‑Hodgkin lymphoma in children and adolescents

  This protocol will try giving rituximab earlier and more intensively alongside intensified chemotherapy for children and teens with aggressive mature B‑cell non‑Hodgkin lymphoma to improve event‑free and overall survival.

  Recruiting Phase 2/3 Children's Cancer Group, China · Shanghai, Shanghai Municipality · NCT07168980

• CD19 t-haNK and N-803 plus rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma

  This treatment tests whether giving lab-grown CD19-directed natural killer cells (t-haNK) together with N-803 and rituximab can help adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior therapy.

  Recruiting at 2 sites Phase 2 ImmunityBio, Inc. · Johannesburg and 1 other locations · NCT07125872

• Tirabrutinib versus rituximab plus temozolomide for relapsed or refractory primary central nervous system lymphoma

  This trial tests whether the oral drug tirabrutinib works better alone than the combination of rituximab and temozolomide for people with relapsed or refractory primary CNS lymphoma.

  Recruiting at 42 sites Phase 3 Ono Pharmaceutical Co., Ltd. · Phoenix, Arizona and 41 other locations · NCT07104032

• Epcoritamab plus dose‑adjusted EPOCH‑R for aggressive B‑cell lymphoma

  This trial tests whether adding epcoritamab to dose‑adjusted EPOCH‑R chemotherapy can safely improve outcomes for adults with untreated aggressive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07097363

• Combining pomalidomide, rituximab, orelabrutinib and polatuzumab vedotin for elderly diffuse large B‑cell lymphoma

  This tests whether adding polatuzumab vedotin to a pomalidomide, rituximab and orelabrutinib regimen helps patients aged 70 and older with newly diagnosed diffuse large B‑cell lymphoma.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07072208

• Repeated rituximab infusions for recent-onset type 1 diabetes in adolescents

  This test tries repeated rituximab infusions alongside regular insulin in adolescents 12–17 with recent-onset type 1 diabetes to see if it helps preserve their insulin-producing beta cells.

  Recruiting at 2 sites Phase 2 Pirogov Russian National Research Medical University · Moscow and 1 other locations · NCT07041268

• HLX79 with rituximab (HLX01) for active glomerulonephritis

  This trial will test whether adding HLX79 at different doses to rituximab (HLX01) helps adults with active membranous nephropathy or lupus nephritis.

  Recruiting Phase 2 Shanghai Henlius Biotech · Beijing and 16 other locations · NCT07038382

• Monitoring B cells and rituximab/anti‑rituximab antibodies during rituximab treatment for autoimmune disorders

  This project will test whether checking B-cell counts and rituximab or anti-rituximab levels in the blood can help spot relapses in people with autoimmune cytopenia, connective tissue diseases, or vasculitis who are treated with rituximab.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice, Alpes Maritimes · NCT07037732

• First-line treatment with orelabrutinib plus rituximab for marginal zone lymphoma

  This will test whether taking orelabrutinib together with rituximab works and is safe as a first systemic treatment for adults with marginal zone lymphoma.

  Recruiting at 18 sites Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 17 other locations · NCT07022223

• Rituximab vs multiple approved NMOSD therapies to prevent relapses

  This study tests whether rituximab or one of four other approved medicines is better at preventing NMOSD relapses in adults who have AQP4-IgG.

  Recruiting at 2 sites Phase 4 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07010302

• Tocilizumab plus standard therapy for chronic antibody-mediated rejection after kidney transplant

  This trial will try adding tocilizumab to standard treatment (plasmapheresis, IVIG, and rituximab) to see if it helps people with chronic active antibody-mediated rejection of a kidney transplant.

  Recruiting Shahid Beheshti University of Medical Sciences · Tehran · NCT07006532

• Selinexor with high-dose methotrexate, rituximab, and low-dose whole-brain radiotherapy for newly diagnosed CNS lymphoma patients who can't have transplant

  We will test whether adding oral selinexor to high-dose methotrexate and rituximab followed by low-dose whole-brain radiotherapy can help people with newly diagnosed central nervous system lymphoma who are not candidates for stem cell transplant.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou · NCT07002099

• Pola‑R‑GemOx chemotherapy for relapsed/refractory DLBCL in patients who cannot have an autologous transplant

  This trial will test whether adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin helps people with relapsed or refractory DLBCL who are not eligible for autologous stem‑cell transplant.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07001540

• AlloNK® therapy combined with rituximab for treating certain autoimmune diseases

  This study is testing if a new treatment called AlloNK® combined with rituximab can help people with tough-to-treat autoimmune diseases feel better.

  Recruiting at 52 sites Phase 2 Artiva Biotherapeutics, Inc. · Tuscaloosa, Alabama and 51 other locations · NCT06991114

• Combining Loncastuximab and Roflumilast with R-CHOP for High-Risk Diffuse Large B-cell Lymphoma

  This study is testing a new treatment plan that combines loncastuximab and roflumilast with standard chemotherapy to see if it helps people with high-risk diffuse large B-cell lymphoma do better.

  Recruiting at 2 sites Phase 1 The University of Texas Health Science Center at San Antonio · San Antonio, Texas and 1 other locations · NCT06977711

• ZR-MTX combo for newly diagnosed primary intraocular lymphoma

  This trial tests a Rituximab, Zanubrutinib, and methotrexate cocktail plus intravitreal methotrexate in people newly diagnosed with primary intraocular lymphoma to see if it can extend the time before the disease progresses.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06973811

• Tovorafenib plus rituximab for classical hairy cell leukemia

  This trial tests whether combining tovorafenib and rituximab is safe and effective for adults with relapsed or refractory classical hairy cell leukemia and compares that combination to cladribine plus rituximab in newly diagnosed patients.

  Recruiting at 4 sites Phase 1/2 National Cancer Institute (NCI) · Bethesda, Maryland and 3 other locations · NCT06965114

• Evaluating rituximab for treating chronic fatigue syndrome

  This study is testing if the medication rituximab can help people with chronic fatigue syndrome feel better compared to a placebo.

  Recruiting Phase 2 National Center of Neurology and Psychiatry, Japan · Kodaira, Tokyo · NCT06952413

• New treatment approach for primary central nervous system lymphoma

  This study is testing a new combination of treatments for people with newly diagnosed primary central nervous system lymphoma to see if it can help them respond better and stay healthy longer.

  Recruiting The First Hospital of Jilin University · Changchun · NCT06946407

• Comparing sonrotoclax combinations versus venetoclax plus rituximab for relapsed or refractory CLL/SLL

  This trial will test whether sonrotoclax combined with obinutuzumab or with rituximab works better than venetoclax plus rituximab for adults whose CLL/SLL has come back or not responded to prior treatment.

  Recruiting at 181 sites Phase 3 BeOne Medicines · Laguna Hills, California and 194 other locations · NCT06943872

• Predicting response to low-dose rituximab for rheumatoid arthritis

  We will test whether a blood-based pharmacological model can predict which adults with rheumatoid arthritis will respond to a lower rituximab dose (1000 mg once per cycle).

  Recruiting University Hospital, Tours · Tours · NCT06933134

• Epcoritamab with lenalidomide and rituximab for relapsed or refractory primary diffuse large B‑cell lymphoma of the CNS

  This phase 2 test tries to see if adding epcoritamab to lenalidomide and rituximab helps adults with relapsed or refractory primary CNS diffuse large B‑cell lymphoma.

  Recruiting at 9 sites Phase 2 The Lymphoma Academic Research Organisation · Bordeaux and 12 other locations · NCT06931652

• Golcadomide plus rituximab versus investigator's choice for relapsed or refractory follicular lymphoma

  This trial tests whether combining golcadomide with rituximab works better than standard investigator‑selected treatments for adults with relapsed or refractory follicular lymphoma who have had at least one prior systemic therapy.

  Recruiting at 62 sites Phase 3 Celgene · Birmingham, Alabama and 159 other locations · NCT06911502

• 200 mg rituximab every six months for maintenance in rheumatoid arthritis

  This will test whether giving 200 mg of rituximab every six months keeps rheumatoid arthritis under control in people already on rituximab who have low disease activity.

  Recruiting Phase 4 University Hospital, Strasbourg, France · Strasbourg · NCT06906549

• Bendamustine–Rituximab–Cytarabine plus Zanubrutinib induction followed by zanubrutinib/rituximab with or without sonrotoclax maintenance for newly diagnosed mantle cell lymphoma

  This trial tests whether giving zanubrutinib with a bendamustine‑rituximab‑cytarabine induction and then continuing zanubrutinib with rituximab, with or without sonrotoclax, helps people with newly diagnosed mantle cell lymphoma stay in remission longer.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Phoenix, Arizona and 6 other locations · NCT06854003

• Comparing BGB-16673 to standard treatments for chronic lymphocytic leukemia

  This study is testing a new treatment called BGB-16673 to see if it works better than standard options for people with chronic lymphocytic leukemia who have already tried other therapies.

  Recruiting at 132 sites Phase 3 BeOne Medicines · Jonesboro, Arkansas and 131 other locations · NCT06846671

• Acalabrutinib with rituximab for untreated mantle cell lymphoma in older adults and lower-risk younger patients

  This trial tests whether combining acalabrutinib and rituximab can produce complete remissions at 12 months in people with untreated mantle cell lymphoma who are elderly or younger with low- to intermediate-risk disease.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06846489

• Combination treatment for chronic lymphocytic leukemia and lymphoma

  This study is testing a new combination treatment with sonrotoclax and either zanubrutinib or rituximab to see if it can help patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06839053

• Rituximab plus golcadomide as a chemo-free first-line option for older frail diffuse large B‑cell lymphoma patients using a simplified geriatric assessment

  This treatment tests whether combining rituximab and golcadomide can be an effective chemo-free first-line option for older, frail people newly diagnosed with diffuse large B‑cell lymphoma.

  Recruiting at 18 sites Phase 2 Fondazione Italiana Linfomi - ETS · Alessandria, Alessandria and 19 other locations · NCT06835530

• Using golcadomide and rituximab to prepare patients for CAR T-cell therapy in aggressive B-cell lymphoma

  This study is testing if a combination of golcadomide and rituximab can help patients with aggressive B-cell lymphoma get ready for CAR T-cell therapy.

  Recruiting at 7 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 6 other locations · NCT06834373

• Using RMTT regimen as first-line therapy for primary central nervous system lymphoma

  This study is testing if a new combination treatment called RMTT can help people with primary central nervous system lymphoma who haven't had treatment before.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06832267

• Tafasitamab with lenalidomide and rituximab for newly diagnosed follicular and marginal zone lymphoma

  This trial will test whether adding tafasitamab to rituximab and lenalidomide is safe and helps people newly diagnosed with follicular lymphoma or marginal zone lymphoma.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT06792825

• Comparing BEBT-908 with Rituximab to Standard Chemotherapy for Lymphoma

  This study is testing whether a new treatment called BEBT-908 combined with rituximab can work better than standard chemotherapy for people with relapsed or hard-to-treat diffuse large B-cell lymphoma.

  Recruiting Phase 3 BeBetter Med Inc · Beijing, Beijing Municipality · NCT06792253

• Loncastuximab tesirine plus rituximab as bridging therapy before CAR-T for relapsed or refractory large B‑cell lymphoma

  This trial tries loncastuximab tesirine with rituximab as a bridge before commercial CD19 CAR‑T therapy for adults with relapsed or refractory large B‑cell lymphoma to see if it is safe and helps control disease before CAR‑T.

  Recruiting at 2 sites Phase 2 University of Utah · Chapel Hill, North Carolina and 1 other locations · NCT06788964

• Sintilimab plus rituximab followed by R-CHOP for untreated primary mediastinal DLBCL

  This study will see if giving sintilimab with rituximab first, then switching to R-CHOP chemotherapy, helps people newly diagnosed with primary mediastinal diffuse large B‑cell lymphoma get better responses.

  Recruiting Phase 2 Sun Yat-sen University · Fuzhou, Fujian and 1 other locations · NCT06742502

• Combination therapy for relapsed or refractory primary CNS lymphoma

  This study is testing a new combination of medications to see if it can help people with relapsed or hard-to-treat primary central nervous system lymphoma feel better.

  Recruiting Phase 2 NOBO Medicine · Busan and 9 other locations · NCT06737250

• Using rituximab to achieve remission in patients with chronic inflammatory demyelinating polyneuropathy

  This study is testing if rituximab can help people with chronic inflammatory demyelinating polyneuropathy feel better and reduce their need for other treatments.

  Recruiting Phase 3 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT06714838

• Orelabrutinib plus rituximab versus R‑CVP as first-line treatment for marginal zone lymphoma

  This test will see if orelabrutinib plus rituximab, followed by orelabrutinib maintenance, works as well or better than standard R‑CVP chemotherapy for adults with untreated marginal zone lymphoma.

  Recruiting Phase 2 The First Affiliated Hospital of Nanchang University · Nanchang, Jiangxi · NCT06700798

• Combination therapy for elderly patients with newly diagnosed diffuse large B-cell lymphoma

  This study is testing a new combination treatment for older patients with newly diagnosed diffuse large B-cell lymphoma who can't tolerate standard chemotherapy to see if it helps them feel better and live longer.

  Recruiting Phase 1/2 Zhengzhou University · Zhengzhou, Henan · NCT06683885

• Combination treatment for difficult-to-treat lupus

  This study is testing a new combination treatment with NK010 or NK042 and rituximab to see if it helps people with hard-to-treat lupus feel better.

  Recruiting Phase 1 Guangdong Provincial People's Hospital · Guangzhou, Guangdomg · NCT06676631

• Treatment for elderly patients with newly diagnosed double-expressor lymphoma

  This study is testing a new combination of treatments for older patients with a specific type of lymphoma to see if it helps them feel better and stay in remission.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06674096

• Examining personalized treatment for multiple sclerosis with rituximab and ocrelizumab

  This study is testing whether measuring the levels of two different medications, rituximab and ocrelizumab, can help doctors personalize treatment for people with relapsing-remitting multiple sclerosis who are just starting therapy.

  Recruiting Haukeland University Hospital · Bergen, Vestland · NCT06663111

• Roginolisib with venetoclax and rituximab for relapsed or refractory CLL

  This trial will test whether adding roginolisib to the standard venetoclax plus rituximab treatment helps people with relapsed or refractory CLL get deeper and longer remissions.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06644183

• Avacopan treatment for ANCA-associated vasculitis

  This study is testing if avacopan, used with a lower dose of steroids and rituximab, can help people with newly diagnosed ANCA-associated vasculitis feel better compared to a longer course of steroids.

  Recruiting at 21 sites Phase 4 Chiba University · Toyoake, Aichi-ken and 21 other locations · NCT06611696

• Using loncastuximab tesirine and rituximab after targeted radiation for brain lymphomas

  This study is testing if a combination of two medications, loncastuximab tesirine and rituximab, can help adults with certain types of brain lymphomas after they receive targeted radiation treatment.

  Recruiting at 3 sites Phase 1 University of Utah · Philadelphia, Pennsylvania and 2 other locations · NCT06607549

• Rituximab's effects on cognitive and hand functions in secondary progressive multiple sclerosis

  This study is testing if the medication rituximab can help improve thinking and hand skills in people with secondary progressive multiple sclerosis who have significant disabilities.

  Recruiting Phase 2 Cairo University · Giza, Giza Governorate · NCT06599307

• Evaluating R-CMOP treatment for newly diagnosed diffuse large B-cell lymphoma

  This study is testing a new combination treatment for people with newly diagnosed diffuse large B-cell lymphoma to see if it is safe and effective.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06594640

• Evaluating the safety and efficacy of Rituximab combined with AB-101 for autoimmune diseases

  This study is testing if combining a new treatment called AB-101 with rituximab can safely help adults with certain autoimmune diseases feel better.

  Recruiting Phase 1 IRIS Research and Development, LLC · Plantation, Florida · NCT06581562

• Combining nemtabrutinib and rituximab to treat mantle cell lymphoma

  This study is testing if combining two treatments, nemtabrutinib and rituximab, can help people with newly diagnosed mantle cell lymphoma feel better and live longer.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06572618

• Combination treatment for relapsed or refractory follicular lymphoma

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory follicular lymphoma feel better.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06563596

• Comparing two treatment combinations for Hairy Cell Leukemia

  This study is testing whether a new combination of drugs can work better and cause fewer side effects than the standard treatment for patients with Hairy Cell Leukemia who have a specific genetic mutation.

  Recruiting at 8 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 9 other locations · NCT06561360

• Zanubrutinib with bendamustine and rituximab for untreated Waldenström macroglobulinemia

  This treatment will try zanubrutinib together with bendamustine and rituximab to see if it produces deep responses in people with untreated Waldenström macroglobulinemia.

  Recruiting at 5 sites Phase 2 Massachusetts General Hospital · Denver, Colorado and 4 other locations · NCT06561347

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people aged 18 to 75 with relapsed or refractory diffuse large B-cell lymphoma feel better and improve their chances of recovery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hanzhou, Zhejiang · NCT06554600

• Treatment for newly diagnosed primary central nervous system lymphoma using pomadomide, rituximab, and methotrexate

  This study is testing a new combination of medications, including pomadomide, rituximab, and methotrexate, to see if it can safely help people with newly diagnosed primary central nervous system lymphoma.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hanzhou, Zhejiang · NCT06554561

• Combining AZD0486 with Rituximab for Untreated Follicular Lymphoma

  This study is testing if a new treatment combining AZD0486 with rituximab can help people with untreated follicular lymphoma do better than the usual therapies.

  Recruiting at 121 sites Phase 3 AstraZeneca · Huntsville, Alabama and 243 other locations · NCT06549595

• Rituximab plus MMF for SSc-ILD: does adding rituximab help lung function compared with placebo?

  This trial tests whether adding rituximab to mycophenolate mofetil improves lung function in adults with systemic sclerosis–associated interstitial lung disease compared with MMF alone plus placebo.

  Recruiting Phase 3 University Hospital, Tours · Tours · NCT06549231

• Follow-up on Rituximab treatment for children's nephrotic syndrome

  This study looks at how well rituximab works and its safety for children with hard-to-treat nephrotic syndrome by reviewing their past treatment data.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06530004

• Comparing Pola-ZR2 and ZR2 for treating elderly patients with diffuse large B-cell lymphoma

  This study is testing if adding a new drug called polatuzumab vedotin to a standard treatment helps older patients with diffuse large B-cell lymphoma feel better and improve their outcomes.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT06522555

• Combining Tafasitamab and Lenalidomide with Gemcitabine and Oxaliplatin for treating relapsed DLBCL

  This study is testing a new combination of medications for people with relapsed DLBCL to see if it works better than the standard treatment.

  Recruiting at 3 sites Phase 3 Beijing InnoCare Pharma Tech Co., Ltd. · Beijing and 19 other locations · NCT06521255

• Rituximab plus venetoclax as first treatment for marginal zone lymphoma

  This trial will test whether combining rituximab and venetoclax helps adults with previously untreated marginal zone lymphoma.

  Recruiting Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT06510309

• Combining Orelabrutinib with Bendamustine and Rituximab for treating Mantle Cell Lymphoma

  This study is testing if adding Orelabrutinib to the standard treatment of Bendamustine and Rituximab can help people with intermediate- to high-risk mantle cell lymphoma who can't have a transplant feel better and live longer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT06496308

• CAR-T-cell treatment for high-risk mantle cell lymphoma

  This study is testing a new CAR-T-cell treatment for high-risk mantle cell lymphoma to see if it works better than standard therapies for younger and healthier elderly patients.

  Recruiting at 2 sites Phase 2 Ludwig-Maximilians - University of Munich · Mainz and 1 other locations · NCT06482684

• Combining Orelabrutinib and Rituximab for Treating Marginal Zone Lymphoma

  This study is testing if combining two medications, Orelabrutinib and Rituximab, can help adults with Marginal Zone Lymphoma who haven't responded to other treatments or can't have local therapy.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06478472

• Combining three medications for untreated follicular lymphoma

  This study is testing a new combination of three medications to see if they can effectively treat people with untreated follicular lymphoma without using traditional chemotherapy.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT06471738

• Epcoritamab treatment for patients with large B-cell lymphoma after CAR T-cell therapy

  This study is testing if a new treatment called Epcoritamab, either on its own or with two other drugs, can help patients with large B-cell lymphoma who haven't responded well after CAR T-cell therapy.

  Recruiting at 3 sites Phase 2 Peter MacCallum Cancer Centre, Australia · Camperdown, New South Wales and 5 other locations · NCT06414148

• Using belimumab after rituximab for treating resistant juvenile Sjogren's syndrome

  This study is testing if giving belimumab after rituximab can help children aged 5-18 with tough-to-treat juvenile Sjogren's syndrome feel better.

  Recruiting Phase 4 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06410833

• Combining Pirtobrutinib and Rituximab for treating newly diagnosed Marginal Zone Lymphoma

  This study is testing if combining two medications, Pirtobrutinib and Rituximab, can help people who have just been diagnosed with marginal zone lymphoma feel better.

  Recruiting at 2 sites Phase 2 University of Utah · St Louis, Missouri and 1 other locations · NCT06390956

• Comparing Orelabrutinib with standard treatment for mantle cell lymphoma

  This study is testing if adding a new drug called Orelabrutinib to the standard treatment can help older patients with untreated mantle cell lymphoma feel better and improve their outcomes.

  Recruiting at 19 sites Phase 3 InnoCare Pharma Inc. · Beijing and 38 other locations · NCT06363994

• Treatment to reduce anti-HLA antibodies before stem cell transplantation

  This study is testing a new treatment to lower harmful antibodies in patients with high levels before they receive a stem cell transplant, to see if it helps them have fewer complications and better outcomes.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT06362967

• Combining rituximab and zanubrutinib for treating indolent B-cell lymphomas

  This study is testing if combining two medications, rituximab and zanubrutinib, can help people with untreated indolent B-cell lymphomas feel better and improve their treatment outcomes.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06350318

• Immediate corticosteroids with rituximab as needed to stop ocular myasthenia from spreading

  We will test whether starting corticosteroids right away, and adding rituximab if eye symptoms come back, can prevent recent-onset ocular myasthenia from spreading to other muscles in adults.

  Recruiting at 6 sites Phase 3 Fondation Ophtalmologique Adolphe de Rothschild · Bordeaux and 10 other locations · NCT06342544

• AI-guided personalized rituximab for membranous nephropathy

  This trial will test whether an AI-guided approach to dosing rituximab improves remission in adults with PLA2R1-positive nephrotic membranous nephropathy.

  Recruiting at 13 sites Phase 3 Centre Hospitalier Universitaire de Nice · Besançon and 13 other locations · NCT06341205

• Comparing two drug treatments for low tumor burden follicular lymphoma

  This study is testing whether rituximab or mosunetuzumab works better for people with low tumor burden follicular lymphoma to see which treatment helps them live longer and feel better.

  Recruiting at 263 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 287 other locations · NCT06337318

• Combining rituximab with prior therapies for advanced liver cancer

  This study is testing if adding rituximab to other treatments can help people with advanced liver cancer who haven't had success with previous therapies.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT06301399

• Combination treatment for low and intermediate risk Mantle Cell Lymphoma

  This study is testing a new combination of two drugs, pirtobrutinib and rituximab, to see if it can effectively treat people with low and intermediate risk Mantle Cell Lymphoma without using chemotherapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06263491

• Using Rituximab to treat severe aplastic anemia with platelet transfusion issues

  This study is testing if rituximab can help people with severe aplastic anemia who have trouble getting enough platelets from transfusions.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06254560

• Long-term outcomes in primary membranous nephropathy

  This project will follow adults with primary membranous nephropathy and nephrotic syndrome to see how their disease and real-world treatments affect long-term kidney outcomes.

  Recruiting Mario Negri Institute for Pharmacological Research · Bergamo, BG and 1 other locations · NCT06242327

• Combining CC-99282 with Rituximab for Non-Hodgkin's Lymphoma Treatment

  This study is testing a new combination of a pill called CC-99282 and an infusion called rituximab to see if it helps people with non-Hodgkin's lymphoma who didn't respond well to previous treatments.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06209619

• Comparing Rituximab Injection and Radiation Therapy for Ocular Lymphoma

  This study is testing whether an injection of Rituximab works as well as radiation therapy for treating a type of eye lymphoma, to see which option is safer and more effective for patients.

  Recruiting Zhongshan Ophthalmic Center, Sun Yat-sen University · Guangzhou, Guangdong · NCT06190301

• Treatment for Richter Syndrome using Glofitamab with Rituximab or Obinutuzumab plus CHOP

  This study is testing if a new treatment combining Glofitamab with Rituximab or Obinutuzumab and CHOP chemotherapy can help people with untreated Richter Syndrome feel better.

  Recruiting at 6 sites Phase 2 French Innovative Leukemia Organisation · Amiens and 22 other locations · NCT06186648

• Testing a new drug combination for relapsed or refractory follicular and marginal zone lymphoma

  This study is testing a new combination of drugs to see if it can help adults with relapsed or hard-to-treat follicular or marginal zone lymphoma feel better compared to standard treatment.

  Recruiting at 167 sites Phase 3 Regeneron Pharmaceuticals · Los Angeles, California and 170 other locations · NCT06149286

• Combining Zanubrutinib with Bendamustine and Rituximab for Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma

  This study is testing if combining a new drug called Zanubrutinib with two other treatments can help older patients with newly diagnosed mantle cell lymphoma feel better and improve their health.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06136351

• Testing a new treatment for relapsed marginal zone lymphoma

  This study is testing a new combination of Orelabrutinib and rituximab to see if it helps people with relapsed marginal zone lymphoma who haven't had success with other treatments.

  Recruiting at 3 sites Phase 4 Ningbo No. 1 Hospital · Hangzhou, Zhejiang and 2 other locations · NCT06134284

• Odronextamab with chemo vs rituximab with chemo in untreated DLBCL

  A new treatment approach using odronextamab plus chemotherapy is being tested to see if it works better and is as safe as rituximab plus chemotherapy for adults with newly diagnosed diffuse large B-cell lymphoma.

  Recruiting at 182 sites Phase 3 Regeneron Pharmaceuticals · Scottsdale, Arizona and 194 other locations · NCT06091865

• Testing a new drug called odronextamab for treating follicular lymphoma

  This study is testing a new drug called odronextamab to see if it can safely and effectively treat people with follicular lymphoma who haven't received treatment before.

  Recruiting at 145 sites Phase 3 Regeneron Pharmaceuticals · Tucson, Arizona and 189 other locations · NCT06091254

• Combining Orelabrutinib with Lenalidomide and Rituximab for treating relapsed Marginal Zone Lymphoma

  This study is testing if adding a new drug called Orelabrutinib to the standard treatment of Lenalidomide and Rituximab can help people with relapsed Marginal Zone Lymphoma feel better and improve their outcomes.

  Recruiting at 16 sites Phase 3 Beijing InnoCare Pharma Tech Co., Ltd. · Bengbu, Auhui and 18 other locations · NCT06082102

• Combining Epcoritamab with Rituximab-mini CVP for Older Patients with Newly Diagnosed Large B-cell Lymphoma

  This study is testing if adding a new drug called epcoritamab to the standard treatment for older patients with newly diagnosed large B-cell lymphoma can improve their chances of recovery.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06045247

• Optimizing Rituximab Tapering Strategies for Rheumatoid Arthritis

  This study is testing two different ways to reduce the dose of rituximab in people with rheumatoid arthritis to see which method helps them feel better and manage their condition more effectively.

  Recruiting at 5 sites Phase 4 Universitaire Ziekenhuizen KU Leuven · Merksem, Antwerpen and 6 other locations · NCT06003283

• New treatment approach for newly diagnosed mantle cell lymphoma

  This study is testing a new treatment plan for people with newly diagnosed mantle cell lymphoma to see if it can help them achieve better remission rates and improve their overall health.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT05992597

• Combining Rituximab and Telitacicept for treating ANCA-associated Vasculitis

  This study is testing if adding Telitacicept to Rituximab treatment can help people with ANCA-associated vasculitis stay in remission longer.

  Recruiting Phase 4 Chinese SLE Treatment And Research Group · Beijing · NCT05962840

• Treatment for elderly patients with untreated diffuse large B-cell lymphoma

  This study is testing a new treatment combining acalabrutinib and rituximab for older or frail patients with untreated diffuse large B-cell lymphoma to see if it works better than standard chemotherapy.

  Recruiting at 46 sites Phase 2 AstraZeneca · Berkeley, California and 56 other locations · NCT05952024

• Comparing two treatments for relapsed chronic lymphocytic leukemia

  This study is testing if a new combination of two drugs, nemtabrutinib and venetoclax, can help people with relapsed chronic lymphocytic leukemia live longer without their cancer getting worse compared to the usual treatment.

  Recruiting at 103 sites Phase 3 Merck Sharp & Dohme LLC · Springdale, Arkansas and 105 other locations · NCT05947851

• Personalized maintenance therapy versus standard treatment for pemphigus

  This trial tests whether using biomarkers to personalize rituximab maintenance therapy helps adults with moderate-to-severe pemphigus stay in remission longer than standard treatment.

  Recruiting at 23 sites Phase 4 University Hospital, Rouen · Amiens and 33 other locations · NCT05898308

• Comparing two immunotherapy agents for treating a specific type of lymphoma

  This study is testing whether a new immunotherapy called mosunetuzumab works better than the standard treatment rituximab for people with a specific type of lymphoma.

  Recruiting at 34 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 36 other locations · NCT05886036

• Treatment for relapsed mantle cell lymphoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with relapsed mantle cell lymphoma who haven't had success with other treatments.

  Recruiting Phase 2 Medical University of Vienna · Vienna · NCT05868395

• Comparing Rituximab and Ocrelizumab for Treating Relapsing Multiple Sclerosis

  This study is testing if rituximab works just as well as ocrelizumab for treating relapsing multiple sclerosis in adults.

  Recruiting Phase 3 Amsterdam UMC, location VUmc · Amsterdam · NCT05834855

• Combining Acalabrutinib with R-miniCHOP for older adults with untreated diffuse large B-cell lymphoma

  This study tests if adding Acalabrutinib to the usual treatment for older adults with untreated diffuse large B-cell lymphoma can help them live longer without their cancer getting worse.

  Recruiting at 9 sites Phase 3 Universität des Saarlandes · Homburg, Saarland and 16 other locations · NCT05820841

• Combination treatment of tafasitamab and rituximab for post-transplant lymphoma

  This study is testing if a combination of two medications, tafasitamab and rituximab, can effectively treat lymphoma that develops after organ transplants.

  Recruiting at 4 sites Phase 2 Ohio State University Comprehensive Cancer Center · New Brunswick, New Jersey and 3 other locations · NCT05786040

• Epcoritamab plus rituximab as first treatment for follicular lymphoma

  This trial tests whether adding epcoritamab to rituximab is safe and effective as the first treatment for adults with untreated follicular lymphoma.

  Recruiting at 6 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 5 other locations · NCT05783609

• Comparing Rituximab and Ocrelizumab for Relapsing-Remitting Multiple Sclerosis

  This study is testing whether rituximab can work just as well as ocrelizumab in helping people with relapsing-remitting multiple sclerosis manage their symptoms over two years.

  Recruiting at 9 sites Phase 3 Rennes University Hospital · Lyon, Bron and 22 other locations · NCT05758831

• Combination treatment for relapse refractory central nervous system lymphoma

  This study is testing a new combination of three medications to see if it can help people with hard-to-treat central nervous system lymphoma feel better.

  Recruiting Phase 1/2 Huashan Hospital · Hefei, Anhui and 4 other locations · NCT05698147

• Treatment of Primary Membranous Nephropathy with SNP-ACTH Gel

  This study is testing a new gel treatment for primary membranous nephropathy to see if it works better than an existing medication called rituximab.

  Recruiting at 31 sites Phase 3 Cerium Pharmaceuticals, Inc. · Los Angeles, California and 30 other locations · NCT05696613

• New treatment approach for pediatric patients with relapsed B-cell leukemia

  This study is testing a new combination treatment for kids with relapsed B-cell leukemia to see if it helps them get better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05645718

• Combining Zanubrutinib and Rituximab for Indolent Mantle Cell Lymphoma

  This study is testing if a new combination of two medications, zanubrutinib and rituximab, can help people with indolent mantle cell lymphoma who haven't been treated before.

  Recruiting at 13 sites Phase 2 University College, London · Derby and 12 other locations · NCT05635162

• Treatment for patients with relapsed or refractory Non-Hodgkin Lymphoma

  This study is testing a new treatment for patients with relapsed or hard-to-treat Non-Hodgkin Lymphoma to see if it can help them feel better and improve their condition.

  Recruiting at 2 sites Phase 1 ImmunityBio, Inc. · Newport Beach, California and 1 other locations · NCT05618925

• Combination treatment for newly diagnosed primary central nervous system lymphoma

  This study is testing a new combination of treatments for people with newly diagnosed primary central nervous system lymphoma to see if it helps them respond better and live longer.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hanzhou, Zhejiang · NCT05600660

• Combination treatment for patients with primary central nervous system lymphoma

  This study is testing a new combination of treatments for adults with primary central nervous system lymphoma who can't have high-dose chemotherapy to see if it helps them get better and live longer.

  Recruiting Phase 2 University of Cologne · Stuttgart, Baden-Wurttemberg and 5 other locations · NCT05583071

• Comparing immediate and delayed treatments for children with anti-MOG antibody-related acute demyelinating syndromes

  This study is testing whether starting treatment right away with Azathioprine or Rituximab can help children with anti-MOG antibody-related acute demyelinating syndromes do better in the long run compared to waiting for treatment.

  Recruiting Phase 3 Assistance Publique - Hôpitaux de Paris · Besançon and 8 other locations · NCT05545384

• Treatment of Primary Membranous Nephropathy with Rituximab and Corticosteroids

  This study is testing whether combining rituximab with corticosteroids works better than just rituximab alone for treating primary membranous nephropathy in people who haven't been treated before.

  Recruiting Phase 4 First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT05514015

Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.

Quick answers

How many clinical trials of Rituximab are recruiting right now?

176, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 50 countries. The most sites are in China (73 trials), United States (64 trials), France (27 trials), Italy (15 trials), Germany (15 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 90, Phase 3: 31, Phase 4: 13, Phase 1/2: 12. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →